Maurice Mannesse

Maurice Mannesse is a seasoned professional in the pharmaceutical development sector, currently serving as VP CMC at ProQR Therapeutics since June 2025. Prior experience includes senior roles at Leyden Labs as Senior Director and Director of CMC from March 2022 to May 2025, and leading CMC Portfolio Management at uniQure from November 2021 to March 2022. Maurice has an extensive background at HAL Allergy Group, where responsibilities included Director of CMC Development and Head of Process Development from March 2013 to October 2021. Earlier career achievements encompass positions at DORC International B.V., Xendo Pharma Services, and Pharming, where significant contributions were made to research and development, particularly in therapeutic glycoproteins. Academic credentials include a PhD in Protein Chemistry/Biochemistry and an MSc in Chemistry from Utrecht University, complemented by a BSc in Microbiology.